Confirmation of pre-existing metastases and safe cisplatin dose.
figure
posted on 2024-03-25, 17:28 authored by Chiara Pastori, Ebtesam H. O. Nafie, Mukta S. Wagh, Stephen J. Hunt, Robert E. Neal IIThe graph indicates the recorded body weight of Naïve Balb/c mice intravenously dosed (tail vein) with 1, 2, 4, and 8 mg/kg of cisplatin once per week for 14 consecutive weeks.
(JPG)
History
Usage metrics
Keywords
study evaluates whetherslows tumor growthsignificant immunostimulatory damagepulsed electric fieldprolongs survival relativeimmunostimulatory tumor microenvironmentimmunostimulatory effect sufficientgaining clinical momentumfavorable safety profilereverse metastatic diseasedemonstrated metastatic diseasepreclinical investigations demonstratexlink "> chemopartial pef ablationimmunotherapy improves localneoadjuvant systemic therapiesmetastatic responsesystemic standardpreclinical settingsneoadjuvant chemofocal therapiesunresectable tumorsunresectable populationsnovel formimprove outcomesimmunotherapy standarddata suggestcombinatorial benefitcisplatin chemotherapyblood cytokinesaffords pef1 immunotherapy&# 945
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC